Today: 20 May 2026
Browse Category

NASDAQ:CMND 13 November 2025 - 18 November 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine reported positive safety results from the first cohort of its FDA-approved Phase I/IIa trial of CMND-100 for alcohol use disorder. No serious adverse events were observed among six participants treated at Johns Hopkins and Yale. CMND shares surged to $0.39 intraday on heavy volume before settling near $0.27 by mid-afternoon November 18. The company also announced a new Israeli patent filing and an expected equity offering.
18 November 2025
··
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine shares surged Thursday after the company received final approval to expand its FDA-regulated Phase 1/2a trial for Alcohol Use Disorder to Hadassah Medical Center in Jerusalem. The firm also filed for a registered direct offering of shares and pre-funded warrants, raising new capital but prompting dilution concerns among investors. The trial now includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah.
13 November 2025
··

Stock Market Today

  • Target Q1 CY2026 Earnings Beat Expectations with 6.7% Sales Growth
    May 20, 2026, 8:18 AM EDT. Target (NYSE:TGT) reported Q1 CY2026 revenue of $25.44 billion, 6.7% higher year on year and beating analyst estimates by 3.4%. Adjusted earnings per share (EPS) came in at $1.71, 17.3% above consensus. The company forecasts 4% net sales growth for full year 2026, up 2 percentage points from prior guidance. Operating margin declined to 4.5% from 6.2% a year ago, while free cash flow loss narrowed to $319 million. Same-store sales rose 5.6% year on year, reversing a prior decline. CEO Michael Fiddelke highlighted stronger-than-expected results and positive response to Target's strategic focus. With a $57.79 billion market capitalization, Target faces growth challenges amid market saturation but aims to leverage scale and innovation moving forward.

Latest articles

Hasbro’s Magic Keeps Wall Street Looking at the Stock

Hasbro’s Magic Keeps Wall Street Looking at the Stock

20 May 2026
Hasbro reported first-quarter revenue of $1 billion, beating estimates, with adjusted earnings per share at $1.47. Magic: The Gathering drove a 26% jump in Wizards and Digital Gaming revenue. Operating profit rose 58% to $270 million. The company maintained its 2026 outlook but cited ongoing risks from cyber costs and tariffs.
VF Stock Moves Higher After Company Says Growth Is Returning

VF Stock Moves Higher After Company Says Growth Is Returning

20 May 2026
VF Corp reported its first full-year revenue growth in three years, with fourth-quarter revenue rising to $2.17 billion, beating Wall Street estimates. Adjusted earnings were break-even. The company reinstated annual guidance for fiscal 2027 and kept its dividend at 9 cents a share. Shares rose 8.2% premarket to $18.11.
Lowe’s Beat Wall Street. Why Investors Still Sold the Stock

Lowe’s Beat Wall Street. Why Investors Still Sold the Stock

20 May 2026
Lowe’s posted quarterly sales of $23.08 billion and adjusted earnings of $3.03 per share, both above analyst estimates, but shares fell 3% premarket as investors focused on weak U.S. housing trends. Comparable sales rose 0.6%, driven by online growth and contractor demand. The company kept its 2026 outlook unchanged. U.S. mortgage rates climbed to 6.56% last week, weighing on home sales and renovations.
Go toTop